Pharming Group N.V.PHARNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.28% | +14.10% | +42.29% | +25.92% | +29.98% |
| Gross Profit Growth | +16.56% | +8.58% | +49.94% | +27.58% | +32.61% |
| EBITDA Growth | +50.83% | +127.55% | +0.00% | +0.00% | +222.95% |
| Operating Income Growth | +115.30% | +527.13% | +0.00% | +0.00% | +285.18% |
| Net Income Growth | -129.85% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -132.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -132.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -21.23% | -18.90% | -20.24% | -21.10% | +3.53% |
| Weighted Average Shares Diluted Growth | -21.23% | -18.90% | -20.24% | -21.10% | +3.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +175.15% | -19.40% | +0.00% | +0.00% | +209.24% |
| Free Cash Flow Growth | +176.28% | -18.24% | +0.00% | +0.00% | +220.63% |
| Receivables Growth | +25.75% | +17.73% | +32.42% | +11.75% | -22.94% |
| Inventory Growth | +23.10% | -1.83% | +14.60% | +15.31% | -8.10% |
| Asset Growth | +3.07% | -13.58% | -1.49% | +14.94% | -5.16% |
| Book Value per Share Growth | +44.35% | +24.59% | +40.59% | +47.21% | -3.56% |
| Debt Growth | -18.07% | -34.53% | -23.11% | +12.66% | -12.25% |
| R&D Expense Growth | -0.15% | +91.86% | +14.15% | +9.80% | +12.85% |
| SG&A Expenses Growth | +22.13% | +0.00% | +25.85% | +6.40% | +16.15% |